Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia

Pernicious Anemia Clinical Trial

Official title: Megadose of Hydroxocobalamin (Vitamin B12) for the Treatment of Pernicious Anemia

Status Completed

Clinical Trial Summary

Demonstrate the effectiveness of a single dose of a multivitamin complex for the treatment of megaloblastic anemia

Clinical Trial Description

The investigators will administrate a single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg. To assess response to treatment, a complete blood count (CBC) will be performed weekly during the first month of treatment, after the first month a CBC will be taken monthly for 6 months. Also to confirm the diagnosis and assess response the investigators will measure levels of methylmalonic acid, homocysteine, and hydroxocobalamin at the beginning of the study, 3 and 6 months. ;

Related Conditions & MeSH terms

• Anemia
• Megaloblastic Anemia Nos
• Pernicious Anemia

• NCT number: NCT03372447
• Study type: Interventional
• Source: Hospital Universitario Dr. Jose E. Gonzalez
• Status: Completed
• Phase: Phase 4
• Start date: December 27, 2017
• Completion date: December 1, 2019